Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
Novocure (NVCR) announced its participation in the 2024 World Conference on Lung Cancer, showcasing new analyses on Tumor Treating Fields (TTFields) therapy for non-small cell lung cancer (NSCLC). A post-hoc analysis of the LUNAR trial revealed no difference in overall survival benefit between patients with different BMIs, while simulation data suggested TTFields can be delivered effectively across various BMIs.
The LUNAR trial met its primary endpoint, demonstrating significant extension in overall survival for NSCLC patients treated with TTFields and standard therapies. Novocure has submitted data to regulatory agencies and anticipates treating patients in late 2024. The company will present posters and participate in symposia at the conference, focusing on TTFields' potential in lung cancer treatment.
Novocure (NVCR) ha annunciato la propria partecipazione alla Conferenza Mondiale sul Cancro ai Polmoni 2024, presentando nuove analisi sulla terapia con Campi Trattanti i Tumori (TTFields) per il cancro ai polmoni non a piccole cellule (NSCLC). Un analisi post-hoc del trial LUNAR ha rivelato che non c'è differenza nel beneficio globale di sopravvivenza tra i pazienti con diversi BMI, mentre i dati di simulazione hanno suggerito che i TTFields possono essere somministrati efficacemente attraverso vari BMI.
Il trial LUNAR ha raggiunto il suo obiettivo principale, dimostrando un'estensione significativa nella sopravvivenza globale per i pazienti NSCLC trattati con TTFields e terapie standard. Novocure ha presentato dati alle agenzie regolatorie e prevede di trattare i pazienti entro la fine del 2024. L'azienda presenterà poster e parteciperà a simposi durante la conferenza, focalizzandosi sul potenziale dei TTFields nel trattamento del cancro ai polmoni.
Novocure (NVCR) anunció su participación en la Conferencia Mundial sobre Cáncer de Pulmón 2024, presentando nuevos análisis sobre la terapia con Campos Tratantes de Tumores (TTFields) para el cáncer de pulmón no microcítico (NSCLC). Un análisis post-hoc del ensayo LUNAR reveló que no hay diferencia en el beneficio de supervivencia general entre pacientes con diferentes IMCs, mientras que los datos de simulación sugirieron que los TTFields pueden administrarse de manera efectiva a través de varios IMCs.
El ensayo LUNAR cumplió su objetivo principal, demostrando una extensión significativa en la supervivencia general para los pacientes NSCLC tratados con TTFields y terapias estándar. Novocure ha presentado datos a las agencias reguladoras y anticipa tratar pacientes a finales de 2024. La compañía presentará carteles y participará en simposios durante la conferencia, enfocándose en el potencial de los TTFields en el tratamiento del cáncer de pulmón.
Novocure(NVCR)는 2024 세계 폐암 회의에 참여하여 비소세포 폐암(NSCLC)을 위한 종양 치료 분야(TTFields) 요법에 대한 새로운 분석 결과를 발표했습니다. 사후 분석에 따르면 LUNAR 시험에서 다양한 BMI를 가진 환자들 간의 전체 생존 혜택에는 차이가 없었습니다. 가상 데이터는 다양한 BMI에서도 TTFields가 효과적으로 전달될 수 있음을 시사했습니다.
LUNAR 시험은 TTFields 및 표준 요법으로 치료받은 NSCLC 환자의 전체 생존기간이显著延长된 것을 보여주며 주요 목표를 달성했습니다. Novocure는 규제 기관에 데이터를 제출했으며 2024년 말에 환자 치료를 계획하고 있습니다. 회사는 회의에서 TTFields의 폐암 치료 가능성에 중점을 두고 포스터 발표와 심포지움에 참여할 것입니다.
Novocure (NVCR) a annoncé sa participation à la Conférence Mondiale sur le Cancer du Poumon 2024, présentant de nouvelles analyses sur la thérapie des Champs de Traitement des Tumeurs (TTFields) pour le cancer du poumon non à petites cellules (NSCLC). Une analyse post-hoc de l'essai LUNAR a révélé qu'il n'y avait pas de différence dans le bénéfice de survie globale entre les patients ayant des IMC différents, tandis que les données de simulation ont suggéré que les TTFields pouvaient être délivrés efficacement à travers divers IMC.
L'essai LUNAR a atteint son objectif principal, montrant une extension significative de la survie globale pour les patients NSCLC traités avec TTFields et les thérapies standard. Novocure a soumis des données aux agences réglementaires et prévoit de traiter des patients d'ici fin 2024. L'entreprise présentera des affiches et participera à des symposiums lors de la conférence, en se concentrant sur le potentiel des TTFields dans le traitement du cancer du poumon.
Novocure (NVCR) hat seine Teilnahme an der Weltkonferenz über Lungenkrebs 2024 bekannt gegeben, bei der neue Analysen zur Tumorbehandlung mit Feldern (TTFields) bei nicht-kleinzelligem Lungenkrebs (NSCLC) präsentiert werden. Eine post-hoc Analyse der LUNAR-Studie ergab keinen Unterschied im Gesamtüberlebensvorteil zwischen Patienten mit unterschiedlichen BMI, während Simulationsdaten darauf hindeuteten, dass TTFields effektiv über verschiedene BMI hinweg verabreicht werden können.
Die LUNAR-Studie erreichte ihr primäres Ziel, das eine signifikante Verlängerung des Gesamtüberlebens für NSCLC-Patienten zeigte, die mit TTFields und Standardtherapien behandelt wurden. Novocure hat Daten an die Regulierungsbehörden übermittelt und rechnet damit, bis Ende 2024 Patienten zu behandeln. Das Unternehmen wird Poster präsentieren und an Symposien auf der Konferenz teilnehmen, bei denen der Fokus auf dem Potenzial von TTFields in der Behandlung von Lungenkrebs liegen wird.
- LUNAR trial met its primary endpoint, showing statistically significant and clinically meaningful extension in overall survival for NSCLC patients
- Post-hoc analysis showed no difference in overall survival benefit between patients with different BMIs, suggesting broad applicability
- Simulation data indicates TTFields can be delivered effectively across various BMIs
- Regulatory submissions completed, with potential patient treatment starting in late 2024
- None.
ROOT,
“We are eager to share these exciting new analyses with the lung cancer community,” said Nicolas Leupin, MD, Novocure’s Chief Medical Officer. “TTFields therapy offers significant potential for the treatment of this prevalent disease. With multiple regulatory reviews underway, there is no better time to examine the promise of TTFields use in the treatment of NSCLC.”
The new post-hoc analysis evaluated survival data from the phase 3 LUNAR clinical trial, as well as a data from a simulation study, to assess the effect of body mass index (BMI) on overall survival (OS) and the feasibility of delivering TTFields at a therapeutic intensity to patients of varying BMIs. Investigators did not identify a difference in OS benefit between patients with a BMI <25 kg/m2 compared a BMI >25 kg/m2. Additionally, data from the simulation-based study suggests TTFields can be delivered to the lungs in therapeutic dose and a corresponding clinical benefit observed in patients across a range of BMIs.
The LUNAR trial was designed to evaluate the use of TTFields therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer, following progression on or after platinum-based therapy. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful extension in OS for patients treated with TTFields and standard systemic therapies, as well as a pronounced extension in OS for patients randomized to receive physician’s choice immune checkpoint inhibitor together with TTFields. Novocure has submitted these data to regulatory agencies for approval and anticipates treating patients in late 2024.
Novocure’s presence at the 2024 WCLC will include:
- Sunset Seminar: Women in Thoracic Oncology, hosted by Women Leaders in Oncology (WLO), sponsored by Novocure, on September 8, 2024, at 6:00 p.m. UTC-7
- Impact of BMI on TTFields in Patients with mNSCLC: Post-hoc Analysis from the Phase 3 LUNAR Study and Simulation Model Data. Poster P1.098B.04 displayed in the Exhibit Hall on September 8, 2024, at 12:00 p.m. UTC-7
- Treatment of Non-Small Cell Lung Carcinoma (NSCLC) Cells With Tumor Treating Fields (TTFields) and DNA-Dependent Protein Kinase (PK) Inhibitors. E-Poster EP.03F.04
-
Tumor Treating Fields (TTFields) Induce Pro-Inflammatory Phenotype Skewing of Macrophages. E-Poster EP.03G.03
ABOUT TUMOR TREATING FIELDS THERAPY
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com.
ABOUT LUNAR
LUNAR tested the safety and effectiveness of TTFields therapy when used together with either an immune checkpoint inhibitor (ICI) or docetaxel for the treatment of patients diagnosed with metastatic NSCLC following progression on or after the use of platinum-based therapy. Patients randomized to receive TTFields therapy together with standard therapies (n=137) demonstrated median overall survival (OS) of 13.2 months compared to 9.9 months in patients treated with standard therapies alone (n=139). Patients randomized to receive TTFields therapy and physician’s choice ICI (n=66) demonstrated a median OS of 18.5 months versus a median OS of 10.8 months in patients treated with an ICI alone (n=68; HR=0.63; P=0.03). Patients randomized to receive TTFields therapy and docetaxel (n=71) had a positive survival trend with a median OS of 11.1 months vs 8.7 months in patients treated with docetaxel alone (n=71). TTFields therapy was well-tolerated with no added systemic toxicities and few grade 3 (no grade 4 or 5) device-related adverse events.
ABOUT NOVOCURE
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Headquartered in Root,
FORWARD-LOOKING STATEMENTS
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240814902295/en/
INVESTORS:
Ingrid Goldberg
investorinfo@novocure.com
MEDIA:
Catherine Falcetti
media@novocure.com
Source: Novocure
FAQ
What were the key findings of Novocure's LUNAR trial for NSCLC presented at WCLC 2024?
When does Novocure (NVCR) expect to start treating NSCLC patients with TTFields therapy?
What presentations will Novocure (NVCR) make at the 2024 World Conference on Lung Cancer?
How did body mass index (BMI) affect the efficacy of TTFields therapy in Novocure's NSCLC study?
